This agreement, which will initially last for 3 years, provides for collaboration in the framework of the project Identification and potential new antibodies and support in performance evaluation and improvement of autoantibody test systems related to neuronal inflammatory diseases.
The project consists of different phases, including investigating new autoantigens, verifying prototype diagnostic tests, and validating and optimizing these tests so that they can reach the market.
EUROIMMUN develops, produces, and sells tests for diagnosing diseases, together with software and automated solutions for developing and using these tests. Previous collaborations between the research group of Dalmau and the company have resulted in diagnostic tests for several diseases, such as encephalitis mediated by antibodies to NBDA, AMPA, and GABAA receptors. These tests are now being used around the world.
The agreement was reached with the mediation of the Innovation Management Office (KTT).